Viewpoints

Reactions to the emergence of novel immunotherapy agents for treatment of bladder cancer, including increased administration in community urology practices, and recommendations for sequencing newer therapies into treatment algorithms.

Neal Shore, MD, FACS; Bobby Liaw, MD; Vivek K. Narayan, MD, MS; and Ashley E. Ross, MD, PhD, share key insights on advances in the use of androgen receptor inhibitors (ARIs) and discuss the urologist’s role in managing patients with mCSPC and nmCRPC.

Experts in treating prostate cancer highlight recent clinical data and discuss practical implications for patient care.